Tianjin Anding Hospital

Running trials

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study on Clinical Characteristics of Patients With Probable Alzheimer's Dementia Stratified by Blood Biomarkers

  NCT07875998· Tianjin Anding Hospital· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Individualized Temporally Interfering Electrical Stimulation in Major Depressive Disorder

  NCT07924917· Tianjin Medical University General Hospital· Source

• Recruiting

  Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

  NCT06757504· Phase 2· Shanghai Auzone Biological Technology Co., Ltd.· Source

• Recruiting

  Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder

  NCT06692361· Gang Wang· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression

  NCT06524505· Tianjin Anding Hospital· Source

• Enrolling by invitation

  Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.

  NCT07162467· Tianjin Anding Hospital· Source

• Enrolling by invitation

  Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms

  NCT07356765· Tianjin Anding Hospital· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia

  NCT07139171· Tianjin Anding Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease5 recruiting
• Schizophrenia5 recruiting
• Depression4 recruiting
• Bipolar disorder3 recruiting
• Autism1 recruiting

Closed trials

• Completed

  Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

  NCT06975514· Phase 3· Shanghai Haiyan Pharmaceutical Technology Co., Ltd.· Source

• Completed

  A Phase II Study to Evaluate NH102 for Depression

  NCT06842992· Phase 2· Jiangsu Nhwa Pharmaceutical Co., Ltd.· Source

• Completed

  Amygdala TIS for Depression

  NCT06477276· Ruijin Hospital· Source

• Completed

  A Study of Daridorexant in Chinese Patients With Insomnia Disorder

  NCT06010693· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

• Completed

  Berberine Improving Cognitive Impairments in Schizophrenia

  NCT07359209· Tianjin Anding Hospital· Source

• Completed

  A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

  NCT05919823· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

  NCT04860830· Phase 3· Boehringer Ingelheim· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Schizophrenia46 works · 8 trials
• Depression45 works · 7 trials